Summary
It has been suggested that anti-LPS monoclonal antibodies (MAbs) may provide protection against clinical gram-negative sepsis8,9). E5, a murine monoclonal immunoglobulin M antibody directed against LPS, was obtained from mice immunized with whole cells of the J5 rough mutant of Escherichia coli O111:B4. E5 has been shown to react in vitro with a variety of LPS, specifically with the lipid A moiety, in previous extensive studies8, 10, 11) .
The present study was undertaken to clarify the in vitro ability of E5 to inhibit LPS activity with human phagocytic cells as targets. Exposure of PMN and monocytes/macrophages to LPS in vitro primes the cells to respond to subsequent stimulation by enhanced release of reactive oxygen species3,4). This metabolic response of phagocytic cells produces chemiluminescence (CL) which can be amplified and measured in vitro by the addition of luminol12). The luminol-enhanced system permits the use of a small amount of whole blood to measure CL13). The CL response of whole blood reflects the ability of blood granulocytes to generate oxygen species upon stimulation by a particulate or soluble stimulus13). We used the LPS-primed CL response of whole blood as a parameter for endotoxic activity and examined whether priming of whole blood could be blocked by preincubating a lipid A preparation or various LPS preparations with E5.
Materials and Methods
Blood samples 
Monoclonal antibody
A murine-derived IgM MAb against LPS (E5) was kindly provided by Pfizer Pharmaceuticals Inc., Tokyo, Japan, in an injection form of 2 mg of E5/ml. This antibody has previously been reported to possess potent anti-endotoxin activity in experimental studies10,11).
LPS and lipid A preparations
The following five LPS and lipid A preparations were used: LPS isolated from E. coli O111:B4, E. coli O 55:B5, Klebsiella pneumoniae, Serratia marcescens and Salmonella typhimurium (Sigma Chemical Co., St., Louis, MO, USA) and synthetic lipid A (LA-15-PP) of E. coli (Daiichi Kagaku Co., Tokyo 
Results
CL response of human whole blood primed with LPS and lipid A Figure 1 shows a typical pattern of the priming effect of LPS (100 ng/ml) of E. coli O111:B4 or lipid A (100 ng/ml) of E. coli on the CL response to PMA in human whole blood. LPS or lipid A alone did not induce the CL response of the blood samples, but increased the CL response to PMA following 10 min preincubation, resulting in about 1.3-fold enhancement of the integral CL value above the response of the untreated blood sample. This priming effect of the LPS varied from person to person (Fig. 2) . Inhibition by E5 of the enhanced CL in human whole blood As shown in Fig. 3 , E5 completely suppressed the enhanced CL response to PMA in the blood samples primed with LPS (100 ng/ml) of E. coli O111:B4, when the LPS was incubated with E5 for 30 min prior to Fig. 1 Typical pattern of the priming effect of LPS (100 ng/ml) of E. coli O111:B4 or lipid A (100 ng/ml) on the chemiluminescence response of whole blood by stimulation with PMA in a healthy adult. Maximum response is shown as the perpendicular (dotted line). 
Discussion
It has been shown that LPS primes various PMN-functions involving the production of reactive oxygen species, in terms of the CL responsem). The same investigators reported that rough LPS preparations cause higher CL responses of PMN than the smooth LPS preparations, suggesting that the difference may be due to the more lipophilic character of rough LPS14). In the present study, however, we used whole blood CL instead of PMN-CL as a parameter for endotoxic activity, and five types of smooth LPS and one lipid A as the CL enhancers. These various types of LPS and the lipid A showed clearly the priming effect on the CL response of whole blood after stimulation with PMA. The priming time of whole blood CL was shorter than that of PMN-CL in the absence of serum, 10 min vs. 60 min. Such fast onset of the priming effect of LPS in whole blood may be due to activation of the complement cascade by LPS and/or the enhanced affinity for the cell surface receptors of phagocytic cells through the formation of complexes of LPS with serum LPS-binding protein. However, the priming effect of LPS varied from donor to donor when the same LPS preparation was used. Furthermore, the degree of priming depended on the type of LPS. Nevertheless, these data indicate that human whole blood can be primed for the luminol-dependent CL response by pretreatment with various types of LPS or a synthetic lipid A (LA-15-PP).
These priming effects of LPS or lipid A in human whole blood were significantly suppressed by preincubation of each endotoxin with an anti-LPS MAb, E5. The inhibitory effect of E5 was most potent against LPS of E. coli O111:B4 and was dose-dependent, with less, but statistically significant, inhibition of the priming by other LPS derived from E. coli O55:135, K. pneumoniae, S. marcescens and S. typhimurium. Although the underlying mechanism by which LPS primes PMN is still unknown, the lipid A portion is known to mediate most of the pathologic effects of the toxicity of endotoxin15). Wood and colleagues have reported that E5 binds to various rough and smooth types of LPS preparations, including LPS isolated from species of Escherichia, Klebsiella, Proteus, Pseudomonas, Salmonella, Serratia and Yersinia by using standard immunologic techniques such as enzyme-linked immunosorbent assay, radioimmunoassay and antibody capture assay using immobilized antibody and a chromogenic Limulus amebocyte lysate detection system. In addition, E5 has been shown to bind with avidity to a variety of natural and synthetic lipid A preparations. Accordingly, our finding that E5 blocked the priming effect of a lipid A preparation on the CL response supports the idea that E5 may bind to an epitope of the hydrophobic lipid A region and thereby prevent the attachment of lipid A to its receptors on the target cell membrane to block the priming effect of the endotoxin on the CL response, because E5 and LPS (or lipid A) were incubated prior to being added to the whole blood samples in this study.
In fact, in a multicenter randomized placebo-controlled clinical trial, E5 was shown to reduce significantly the mortality and morbidity of patients with gram-negative sepsis16). The results of recent clinical studies may support the idea that the MAb E5 binds to the endotoxin and facilitates its elimination or detoxification, thereby improving the clinical outcome. At present, it is not known whether the inhibition by E5 of the priming effect of LPS in human whole blood, that is, the inhibition of oxygen radical release, may contribute to the clinical efficacy of E5. However, such activity of E5 seems likely in vivo, since E5 was shown to suppress the synthesis of hydrogen peroxide in the lungs of rats recieving a single injection of LPS").
In conclusion, the present study indicates that E5 has the ability to inhibit the enhanced CL response in human whole blood samples primed with different types of LPS or lipid A. It may be useful for supportive therapy in patients with gram-negative infection such as septicemia and endotoxemia, especially in a case involving serious PMN-mediated organ damage caused by excessive release of toxic products such as oxygen free radicals.
